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Abstract
Background: Human aneuploidy is the leading cause of early pregnancy loss, mental retardation, and multiple
congenital anomalies. Due to the high mortality associated with aneuploidy, the pathophysiological mechanisms of
aneuploidy syndrome remain largely unknown. Previous studies focused mostly on whether dosage compensation
occurs, and the next generation transcriptomics sequencing technology RNA-seq is expected to eventually uncover
the mechanisms of gene expression regulation and the related pathological phenotypes in human aneuploidy.
Results: Using next generation transcriptomics sequencing technology RNA-seq, we profiled the transcriptomes of
four human aneuploid induced pluripotent stem cell (iPSC) lines generated from monosomy × (Turner syndrome),
trisomy 8 (Warkany syndrome 2), trisomy 13 (Patau syndrome), and partial trisomy 11:22 (Emanuel syndrome) as well
as two umbilical cord matrix iPSC lines as euploid controls to examine how phenotypic abnormalities develop with
aberrant karyotype. A total of 466 M (50-bp) reads were obtained from the six iPSC lines, and over 13,000 mRNAs were
identified by gene annotation. Global analysis of gene expression profiles and functional analysis of differentially
expressed (DE) genes were implemented. Over 5000 DE genes are determined between aneuploidy and euploid iPSCs
respectively while 9 KEGG pathways are overlapped enriched in four aneuploidy samples.
Conclusions: Our results demonstrate that the extra or missing chromosome has extensive effects on the whole
transcriptome. Functional analysis of differentially expressed genes reveals that the genes most affected in
aneuploid individuals are related to central nervous system development and tumorigenesis.
Background
Aneuploidy, an abnormal number of chromosomes in
humans, is the result of a gain or loss of a chromosome
during cell division. Human aneuploidy was first discov-
ered in 1959 by Lejeune and colleagues through monos-
omy X, also known as Turner syndrome [1]. This is the
leading cause of early pregnancy loss, mental retardation,
and multiple congenital anomalies [2]. Among first trime-
ster abortions, lethality due to aneuploidy is greater than
that from all other causes combined [3]. Scientists have
always been interested in determining how aneuploidy
affects a fetus, and the molecular mechanisms of this
condition have been studied for a long time. However, the
high mortality rate associated with aneuploidy limits the
capability to study aneuploidy syndromes systematically.
As a result, most of the published gene expression studies
of human aneuploidy involved patients and/or mouse
models of Down syndrome [4-11].
In recent years, several aneuploid human embryonic
stem cell (ESC) lines have been established as models for
studying human aneuploidy syndromes [12-15], which has
expanded the scope of aneuploidy research, leading to
investigations of other syndromes caused by the gain or
loss of a chromosome. Compared with ESC models,
induced pluripotent stem cell (iPSC) models, the success-
ful reprogramming of differentiated human somatic cells
into a pluripotent state, can be applied to more easily
study human disease [16]. Recently, two laboratories
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generated iPSCs from patients with an aneuploid syn-
drome [17,18]. iPSCs were shown to stably maintain the
karyotype of the donors and to behave like ESCs [17]. Due
to the outstanding performance of the RNA-seq method,
analyzing the gene expression profiles of these aneuploid
iPSCs will provide a great way to understand the patholo-
gical mechanisms of human aneuploidy.
Several recent studies based on DNA microarray techni-
ques concluded that an extra or missing chromosome may
have a major effect on gene expression on the particular
chromosome but only a minor effect on the whole
transcriptome [4,8,9,19]. Conversely, some other studies
suggested the extra or missing chromosome has a global
effect on the whole transcriptome that is regulated by
dosage compensation [20,21]. Dosage compensation is a
process that mainly restores gene dosage to a balanced
level between × chromosome and autosomes in mammals
and has been reported in an aneuploid condition [22].
With the influence of dosage compensation, some genes
on the extra or missing chromosome will have no change
in gene product levels compared with disomic controls
[23]. However, Xiong and colleagues found there is no
dosage compensation of the active × chromosome and
revised the current model of dosage compensation with
RNA sequencing, revealing that with application of next
generation sequencing technologies, the mechanism of
gene expression regulation and its related pathological
phenotypes in human aneuploidy eventually can be
discovered [24-26].
To examine how phenotypic abnormalities develop with
aberrant karyotype, we profiled the transcriptomes of four
human iPSC lines by RNA-seq technology on a next gen-
eration sequencing platform. The four iPSC lines were
generated from monosomy × (Turner syndrome), trisomy 8
(Warkany syndrome 2), trisomy 13 (Patau syndrome), and
partial trisomy 11:22 (Emanuel syndrome), which are
seldom associated with postnatal survival. We compared
the gene expression profiles of the four aneuploid iPSCs
with those of two iPSCs generated from umbilical cord
matrix cells (UMCs) as euploid controls and attempted to
discover how the extra or missing chromosome affects the
human transcriptome and the specific transcriptional
changes caused by dosage imbalance. Functional analysis
of differentially expressed (DE) genes allowed us to deter-
mine the significance of several processes in aneuploidy
during embryonic development. The aim of this study was
to explain how aneuploidy disrupts fetal development and
contributes to phenotypic variations in order to better
understand the molecular etiopathology of aneuploidy.
Results
SOLiD transcriptome sequencing of aneuploid and
euploid iPSCs
We generated a highly detailed transcriptome profile for
four aneuploid iPSC and two euploid iPSC clones using
RNA-seq. The creation of iPSCs from UMCs is easy to
achieve and produces large numbers of cells that escape
acquired somatic cell mutations, which were applied as
euploid controls (UMC1 and UMC6). All transcriptome
libraries were generated and sequenced on a SOLiD v3
platform (Applied Biosystems, Foster City, CA, USA). We
obtained 59.5 M and 58.2 M (50-bp) reads from the two
UMC samples and 83.1 ~ 90.7 M (50-bp) reads from the
four aneuploid samples.
Sequenced reads were mapped onto the human genome
(hg19) using Corona Lite (See Methods, detailed mapping
results are given in Table 1A). Approximately 41-47% of
reads from the four aneuploid iPSC lines were uniquely
mapped onto the reference genome, compared to only
24% and 33% reads uniquely mapped in euploid controls.
Table 1 Statistical information of RNA-seq mapping result.
A. Number of reads in each cell line
Sample Total reads Total Mapped Percent Unique Mapped Percent
UMC1 59,478,926 19,119,147 32.14% 14,256,083 23.97%
UMC6 58,161,509 26,559,086 45.66% 19,416,912 33.38%
T8 86,659,524 46,672,781 53.86% 36,393,943 42.00%
T13 90,676,957 49,763,484 54.88% 38,656,136 42.63%
T22 83,120,658 49,582,084 59.65% 38,498,635 46.32%
XO 88,052,908 46,906,900 53.27% 36,512,405 41.47%
B. Gene expression levels. More than 80% genes are moderately expressed.
Expression Level (RPKM) UMC1 UMC6 T8 T13 T22 XO
Low 0.3-1 1755 1762 1817 1831 1933 1850
Medium 1-100 11350 11270 11548 11534 11041 11060
High > 100 299 331 281 255 250 295
Total 13404 13363 13646 13620 13224 13205
A. Number of reads (total reads, mapped reads and unique mapped reads) shows in every cell lines. B. Distribution of all expressed genes among different
expression levels. More than 80% genes are medium expressed.
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Only the uniquely mapped reads were used for further
analysis, most of which (66-77%) were mapped onto
exons. To examine the influence of this mapping discre-
pancy, we conducted a saturation experiment. As shown
in Additional File 1, the data set with the fewest mapped
reads, UMC1, had a saturation curve fairly close to the
horizontal line. Thus, the transcriptome sequencing was
deep enough and the discrepancy between samples can be
eliminated after normalization.
Read densities for each gene were calculated by the
number of uniquely mapped reads per kb per million
mapped reads (RPKM), and over 13,000 mRNAs were
identified by gene annotation (Table 1B). Hierarchical
clustering of gene expression data showed that aneuploid
samples exhibit similar expression profiles (Figure 1),
whereas euploid iPSC clones generated from UMC were
most similar to each other. The expression differences
between aneuploid and euploid iPSC clones were minor
on a global scale, which agrees with the published micro-
array data showing that Turner syndrome iPSCs exhibited
clustering isolated from normal iPSCs with minor
discrepancies [17]. To further investigate the expression
differences between aneuploid and euploid iPSCs, we
calculated Pearson’s correlation coefficients between the
six cell lines. The scatter plots between all aneuploid
iPSCs are presented in Figure 2, and the scatter plots of
UMC1 and UMC6 are presented in Additional File 2. The
correlation analysis showed that the expression differences
at the whole transcriptome level are not significantly
different between aneuploid and euploid clones (Table 2).
Differential gene expression between aneuploid and
euploid iPSCs
We considered a gene to be significantly DE between two
iPSC lines if P-values and Q-values of DEGseq results
were both less than 0.05. If one gene is both up-regulated
or both down-regulated in UMC1 and UMC6 compared
to one aneuploid cell line, it is classified as a “both”
up-regulated or down-regulated gene. We find that more
than 60% of up- or down-regulated genes in aneuploid
clones are “both” up- or down-regulated genes, confirming
the differences between aneuploid and euploid iPSC
Figure 1 Hierarchical clustering results of gene expression data. Four aneuploid iPSC lines are trisomy 8 (T8), trisomy 13 (T13), partial
trisomy 11:22 (T22), and monosomy × (XO). Two euploid iPSC lines are UMC1 and UMC6. Columns represent cell lines and rows represent
genes. Fold change values compared to mock are represented using log2 expression according to the color key on the right.
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clones. The numbers of up- and down-regulated genes in
each aneuploid line were generally similar. There were
more up-regulated genes in trisomy 8 and trisomy 13,
whereas there were more down-regulated genes in trisomy
22 and monosomy × (Figure 3A, Additional File 3).
Compared to previous transcriptome analysis of trisomy
13 and trisomy 8 with DNA microarray [19,20], RNA-seq
data detects more signal of expressed genes. Thus, micro-
array results may not be able to reliably identify differential
expressed genes with small fold change [27], while RNA-
seq technology perform excellently in measuring gene
expression levels with enough depth and sensitivity [28].
We used a more stringent fold change cut-off value to
define DE genes between aneuploid and euploid iPSC
clones (Figure 3B) and found that the number of DE
genes between aneuploid and euploid clones was
decreasing dramatically. With a fold-change cut-off of
1.5, 26-34% of expressed genes were DE, which
decreases to only 6-8% with a fold-change cut-off of 3
and falls even further to 3-4% with a fold-change cut-off
of 5. These results confirm that aneuploidy has a dosage
effect on gene expression levels. We selected two genes,
SLC25A6 (Solute Carrier Family 25, Member 6) and
PRKX (protein kinase X), to validate our RNA-seq
results by quantitative PCR (qPCR) in XO cell line and
euploid cell line. The relative expression levels of both
genes are nearly 2 fold in euploid sample than in XO,
which is in accordance with the differential level of gene
expression by RNA sequencing (Figure 4).
We examined the up or down regulation of all expressed
genes on each chromosome, and we found that transcrip-
tome regulation is ubiquitous on all chromosomes not just
on the extra chromosome or single remaining chromo-
some (Figure 5). In the four aneuploid cell lines, 8-20% of
genes on each chromosome were up regulated, whereas
Figure 2 Pearson’s correlation coefficient scatter plots between all aneuploid iPSCs.
Table 2 Pearson’s correlation coefficients between all
aneuploid and euploid iPSCs.
UMC1 UMC6 T8 T13 T22 XO
UMC1 1 - - - - -
UMC6 0.967 1 - - - -
T8 0.939 0.942 1 - - -
T13 0.924 0.942 0.947 1 - -
T22 0.939 0.925 0.924 0.930 1 -
XO 0.931 0.935 0.932 0.939 0.935 1
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the percentage of down-regulated genes varied between
5% and 24%, a slightly wider range than for up regulation.
The exceptions were chromosome 19 in all four aneuploid
lines, chromosome 3 in trisomy 22, and chromosome 10
in trisomy 8. The exceptional performance of gene expres-
sion regulation on chromosome 19 was very similar
among the four aneuploid samples, with less than 10% of
genes up-regulated and more than 20% down-regulated
(as high as 35% in monosomy X). For chromosome 3 in
trisomy 22, a very low percentage (only 0.7%) of genes
were up regulated, whereas more than 70% of genes on
the same chromosome were down regulated. A similar
situation occurred on chromosome 10 in trisomy 8, with
only 2.9% genes down regulated and 43.3% up regulated.
Notably, the ratio of down-regulated genes on each chro-
mosome of monosomy × is much higher than those on
other three aneuploid cell lines, which may be caused by
the loss of an × chromosome.
Functional profiling of DE genes
The presence of an extra chromosome or absence of a
missing chromosome has various molecular effects on
aneuploid individuals during fetal development. In order
to explore the connection between the functional
Figure 3 DE genes amount between euploid and aneuploid iPSCs. The threshold is P value≤0.05, and Q value≤0.05. A. DE genes are
classified into up- or down-regulated genes with fold change>1.5. B. DE genes are calculated with different cut-offs of fold change (FC).
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categories of DE genes and the symptoms of aneuploidy
syndromes, we sought to elucidate common regulatory
patterns among aneuploid iPSC lines. Functional clus-
tering analysis of DE genes between each aneuploid line
and the two euploid controls was performed using Data-
base for Annotation, Visualization, and Integrated Dis-
covery (DAVID) [29]. Following the online instructions
provided by DAVID, we examined KEGG pathways and
Gene Ontology (GO) terms with P-values less than 0.05
and gene counts more than 2. We identified 28 KEGG
pathways for trisomy 8, 19 KEGG pathways for trisomy
13, 23 KEGG pathways for trisomy 22, and 18 KEGG
pathways for monosomy X. There are nine pathways
appeared in all four aneuploid cell lines: axon guidance,
calcium signaling, focal adhesion, ribosome, MAPK sig-
naling pathway, p53 signaling pathway, vascular smooth
muscle contraction, pathways in cancer and basal cell
carcinoma (Figure 6). GO terms found in all four aneu-
ploid lines are shown in Additional File 4. The biological
processes of GO terms in all aneuploid cell lines were
related to ion transmission, central nervous system, reg-
ulation of apoptosis and cell proliferation which is con-
sistent with those identified KEGG pathways.
Due to the exceptional performance of gene expression
regulation on chromosome 3 in trisomy 22 and chromo-
some 10 in trisomy 8, we performed a functional cluster-
ing compared with chromosome 22 in trisomy 22 and
chromosome 8 in trisomy 8, using chromosome 1 as
Figure 4 Validation of RNA-seq results by qPCR. SLC25A6 and PRKX are selected and performed qPCR experiments for the validation of
mRNA expression. The relative expression values of SLC25A6 and PRKX are nearly 2 fold in euploid sample than in XO. Values are referred to the
respective iPS cell lines.
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a control. We found 8 overlapping KEGG/GO terms
between chromosome 3 and chromosome 22, out of 17
terms for chromosome 22 in trisomy 22, which indicates
there is a functional connection between the chromosome
with abnormally regulated genes, chromosome 3, and the
extra chromosome, chromosome 22, in trisomy 22. How-
ever, we did not find any overlapping KEGG/GO terms
between chromosome 8 and chromosome 10 in trisomy 8,
probably because there are only 4 terms in chromosome 8
in trisomy 8. KEGG/GO terms of DE genes on chromo-
some 3 in trisomy 22 and on chromosome 10 in trisomy 8
are listed in Additional File 5.
In addition, we performed pathway analysis for DE
genes in the four aneuploid iPSC lines relative to euploid
controls using GeneGo Pathway tool (Additional File 6).
Among the common functional groups, pathways related
to development appeared to be the predominate group
among all functional categories. Cell adhesion, cytoskele-
ton remodeling, and immune response were also the main
functional groups identified in each cell line.
Discussion
An extra or missing chromosome has global effects on
gene expression
Our study provides a comprehensive understanding of
four human aneuploid induced pluripotent stem cell
(iPSC) lines and two human euploid iPSC lines by tran-
scriptome profiling with high-throughput next generation
sequencing to obtain datasets of differential expression
genes. Noteworthy, most published works of aneuploidy
gene expression analyses have relied on DNA microarray
techniques [8,10,11,13,19], a methodology based on
hybridization, with well-known limitations such as worse
sensitivity on low expression genes. Here the application
of next generation sequencing technologies on quantifying
gene expression levels help us to better understand the
complexity of aneuploidy gene expression patterns as well
as the relationship between gene expression and patholo-
gical phenotypes.
To investigate how an extra or missing chromosome
affects gene expression in aneuploid cells, Mao and collea-
gues measured the expression of transcripts in different
tissue/cell types of trisomy 21 and found that only chro-
mosome 21 shows significant differential expression rela-
tive to euploid controls [8]. Similarly, Hisakatsu and
colleagues generated artificial trisomy 8 cells and analyzed
the gene expression profiles by microarray data. They
found higher average gene expression on the additional
chromosome 8 but lower average gene expression levels
on all non-trisomic chromosomes [20]. However, David
and colleagues presented transcriptome analyses of human
fetal cells from pregnancies affected with trisomy 21/13
and trisomy 18 amniocyte cells, and the relative expression
levels between chromosomes showed a stable pattern with
no significant differences between individual RNA samples
in microarray experiments [19]. Due to the relatively high
uncertainty of microarray methodology, the discrepancies
between these expression patterns may have resulted from
the differences of specific operations or the selected
tissues. Based on the high quality next generation whole
transcript sequencing results in this study, we propose
that an extra or missing chromosome has extensive effects
on the whole transcriptome. We have measured the gene
expression profiles deeply enough in three trisomy and
Figure 5 Gene regulation distribution on each chromosome. Percentages of DE genes out of all expressed genes on each chromosome are
shown as up-regulated part (A) and down-regulated part (B). On y-axis, breaks in scale are introduced because of the high percentage of
chromosome 10 in T8 and chromosome 3 in T22.
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XO iPSC lines to demonstrate that gene expression regu-
lation occurs on every chromosome of each aneuploid
sample (Figure 5). The percentage of differentially regu-
lated genes on the aneuploid chromosome was not signifi-
cantly different from other diploid chromosomes. A
possible reason is that DE genes on the extra or missing
chromosome influence the gene expression regulation on
other chromosomes. Likewise, another recent work that
using microarray to estimate gene expression value regu-
lated by artificial aneuploidy indicates that the gain of a
single chromosome can indeed result in the up or down
regulation of 140-202 genes with only 5-20% of up or
down regulated genes located on the extra chromosome
[30]. Notably, in each aneuploid cell line, less than one-
third of expressed genes on the particular aneuploid chro-
mosome are up- or down-regulated when the fold-change
Figure 6 Clustered heatmap of KEGG pathway enrichment analysis. Pathways found in more than 2 aneuploid cell lines are shown. The
color intensities indicate enrichment score of each KEGG pathway.
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cut-off value is set to 1.5 (Figure 5). To a certain extent,
this is credible evidence for dosage compensation. Dosage
compensation is commonly observed for sex chromo-
somes according to previous studies, and it could have a
similar influence on the aneuploid chromosome. Other-
wise this phenomenon could be attributed to a buffering
and feedback mechanism.
Aneuploidy mainly affects the development of nervous
system
We investigated how an extra or missing chromosome
leads to molecular effects on aneuploid individuals during
fetal development by profiling the whole transcriptomes of
iPSCs derived from aneuploidy syndromes. In addition to
identifying genes relevant to the aneuploid phenotype, we
used functional profiling to identify significantly disrupted
biological pathways. Nine KEGG pathways were identified
in all four aneuploid iPSC lines: axon guidance, calcium
signaling, focal adhesion, ribosome, MAPK signaling
pathway, p53 signaling pathway, vascular smooth muscle
contraction, pathways in cancer and basal cell carcinoma.
The top three are all associated with nervous system
development.
Axon guidance is an important process in the develop-
ment of central nervous system, in which attractive and
repulsive guidance cues steer axons in the growth cone
along specific pathways [31]. There are several signaling
pathways of guidance molecules, such as Slit-Robo and
Eph/Ephrin, that are also included in the list of GeneGo
pathways (Additional File 6). The Slit-Robo signaling
pathway primarily provides important molecular cues for
axon guidance during the assembly of the nervous system
[32]. Recent research using Robo and Slit gene knockout
mice has indicated that the Slit-Robo interaction is an
integral factor during genesis of the corpus callosum [33]
and the key genes of the Slit-Robo signaling pathway are
also expressed in human fetal brain [34]. Agenesis of the
corpus callosum was observed in mosaic trisomy 8 accord-
ing to two case reports [35,36] and could be found in 19%
of 63 individuals with trisomy 22 [37]. We believe the
absence or hypoplastic state of the corpus callosum in
aneuploid syndromes is related to the affected axon
guidance due to misregulated genes in the Slit-Robo
signaling pathway. On the other hand, Ephrin ligands and
their cognate Eph receptors guide axons during neural
development and are emerging as key players in synapse
formation and plasticity in the central nervous system [38].
The central nervous system anomalies in trisomy 13 have
been reported to include partial agenesis of the corpus
callosum and neuronal heterotopias in the cerebellum
[39], and each aneuploidy shows deficiency in neurodeve-
lopment to a different extent.
The focal adhesion pathway is required for both attrac-
tive and repulsive cues to guide axon to their specific
targets during development of nervous system [40]. Focal
adhesions may have other functions such as cytoskeletal
dynamics control but they mainly affect trisomy pheno-
type by influencing axon guidance pathways. Additionally,
Slit-Robo and Eph/Ephrin, the two axon guidance path-
ways, and the focal adhesion pathway all influence retinal
development [41-43], which has been reported to lead to
an abnormal phenotype in trisomy syndromes [44,45].
It is not surprising that a large number of misregulated
genes are involved in the calcium signaling pathway, as
this is the first messenger of signal transduction pathways.
Ca2+ signals affect axon guidance by mediating the reversal
of neuronal migration induced by slit2 gene or pathway
[46]. They also play a key role in regulating the neuronal
growth cone while mediating growth and turning
responses [47], which might be a minor cause of the cor-
pus callosum agenesis observed in aneuploid syndromes.
Calcium signaling pathway also contributes to phenotype
of aneuploidy with another identified pathway, vascular
smooth muscle contraction, which is directly influenced
by calcium concentration [48]. Many cardiovascular are
diseases are originating from abnormal function in vascu-
lar smooth muscle, especially vascular hypertension. Some
patients with Turner syndrome (TS) had been found with
a higher cardiovascular morbidity [49,50], especially vascu-
lar hypertension. Some patients with Turner syndrome
(TS) had been found with a higher cardiovascular morbid-
ity [49,50]. Alzheimer’s disease might also arise in
aneuploidy syndromes through the alterations of Ca2+
levels to cause disturbances [51].
Aneuploidy and tumorigenesis
Another set of enriched KEGG pathways in all 4 aneu-
ploidy is related to cancer including P53 signaling, path-
ways in cancer and basal cell carcinoma. The question of
how aneuploidy affect cancer initiation and progression has
been studied for over a century [52], though its genetic
basis remains unclear. Most cancers contain cells that pos-
sess a common characteristic of aneuploidy while abnormal
number of chromosomes is essential for tumorigenesis [53].
Trisomy 8 and trisomy 13 has been reported to predis-
pose neoplasms, mainly acute myeloid leukemia (AML),
suggesting roles of an extra 8 or 13 chromosome in
tumorigenesis [54,55]. It has been proved that trisomy 8 is
the most frequent trisomy occurred in AML, which leads
to tumor-specific gene-dosage effects such as significantly
down-regulated apoptosis-regulating genes [56]. Although
there is no explicit association between × chromosome
genes and neoplasm, basal cell carcinoma, another enrich-
ment pathway in our study, was diagnosed in a TS patient
[57,58]. Several recent investigations showed that TS
patients have significantly increased risks of tumor,
especially in central nervous system, bladder and urethra
[57-59].
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Cumulatively, our result together with current evidence
suggests that besides multiple developmental abnormal-
ities, aneuploidy associate with alterations in the risk for
specific cancers. The extra or missing chromosome dis-
rupts global transcription and promotes tumorigenesis
effectively by disturbing cancer related pathways. However,
the characteristic of lethality to aneuploidy increase the
difficulty to investigate whether the gain or loss of a
chromosome contributing to tumorigenesis by down-
regulated the expression of tumor suppressor genes and/
or up-regulated the expression of oncogenes. Further
molecular biological studies are needed to assess, and
more clinical reports are needed to prove how aneuploidy
affects tumorigenesis.
As to the exceptional performance of more DE genes on
chromosome 3 in trisomy 22, 4 KEGG pathways enrich on
that chromosome, which are axon guidance, colorectal
cancer, glycosaminoglycan degradation and endometrial
cancer. Three of them are nervous system and tumorigen-
esis related pathways. This might explain why the down-
regulated genes on chromosome 3 in trisomy 22 are much
more than those on other chromosomes.
Our Gene Ontology analysis confirms our KEGG path-
way results, especially with respect to nervous system
development. The integrated results in this study demon-
strate that genes involved in nervous system development
and tumorigenesis are most affected pathologically in
aneuploid individuals. Our results provide initial indica-
tions of possible biological pathways affected by aneu-
ploidy based on deeply transcriptome sequencing. In
addition, we also offer a better understanding to of the
early etiology of congenital anomalies, which may suggest
promote future innovative approaches in health treatment.
Conclusions
Using next generation transcriptomics sequencing tech-
nology RNA-seq, we profiled the transcriptomes of four
human aneuploid induced pluripotent stem cell (iPSC)
lines generated from monosomy × (Turner syndrome),
trisomy 8 (Warkany syndrome 2), trisomy 13 (Patau syn-
drome), and partial trisomy 11:22 (Emanuel syndrome) as
well as two umbilical cord matrix iPSC lines as euploid
controls. A total of 466 M (50-bp) reads were obtained
from six iPSC lines, and over 13,000 mRNAs were identi-
fied by gene annotation. Global analysis of gene expression
profiles and functional analysis of differentially expressed
(DE) genes were implemented to examine how phenotypic
abnormalities develop with aberrant karyotype. Our results
demonstrate that the extra or missing chromosome has
extensive effects on the whole transcriptome. Functional
analysis of differentially expressed genes reveals that the
genes most affected in aneuploid individuals are related to
central nervous system development and tomorigenesis.
Methods
Next-generation transcriptome sequencing and data
processing
All human iPSC clones presented here were obtained from
the South China Institute for Stem Cell Biology and
Regenerative Medicine, Guangzhou Institutes of Biomedi-
cine and Health, and have been described before [17].
Library construction was based on a protocol described
previously [60,61]. Total RNA of each line was extracted
using TRIzol reagent (Invitrogen) according to the manu-
facturer’s instructions. Poly(A)+ mRNA was isolated from
total RNA using Oligotex (QIAGEN). RNA was fragmen-
ted with RNase III, preparing for constructing transcrip-
tome libraries of each iPSC cell line. Applied Biosystems
SOLiD Whole Transcriptome Analysis Kit (http://solid.
appliedbiosystems.com) were applied to perform reversed
transcription from 140-200 bp isolated RNA fragments
into Single-strand cDNA.
Sequence data were generated using SOLiD3 system
(Applied Biosystems) following the manufacturer’s instruc-
tions. RNA-seq reads were mapped onto the human refer-
ence genome (NCBI37/hg19) with Corona_lite_v4.2.2
software (Applied Biosystems), setting the parameters for
full-length read mapping (50, 45, 40, 35 bp) with 5, 4, 4,
and 3 mismatches. Only reads that uniquely mapped to
the genome and reads for genes corresponding to mRNA
were chosen for subsequent analysis. Reads density for
each gene (shown as RPKM value) was calculated by the
number of uniquely mapped. Hierarchical clustering
was performed in R using the pheatmap package.
Pearson correlation coefficients for each pair of iPSC
lines were calculated using the log2 RPKM values via
cor function in R.
Detection of DE genes
DE genes between aneuploid iPSCs (T8, T13, T22, and
XO) and normal iPSCs (UMC1 and UMC6) were identi-
fied by DEGseq, for which R-packages are available
under Bioconductor (http://www.bioconductor.org/
packages/2.7). DEGseq is a free R package to detect DE
genes between two samples with or without replicates of
RNA sequencing data [62]. MA plot-based method
(where M is the log ratio of the counts between two
experimental conditions for each gene, and A is the two
group average of the log concentrations of the gene) with
a random sampling method (MARS) was selected. DE
genes between 4 aneuploid and 2 euploid samples are
calculated respectively. The raw count of each gene was
used, and function DEGexp was performed for analysis.
A gene was considered to be significantly DE if its
P-value and Q-value were both less than 0.05. For each
gene, the level of change in expression is stated as a fold-
change.
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Functional profiling of DE genes
The Database for Annotation, Visualization, and Integrated
Discovery (DAVID) was used to identify KEGG pathways
and enriched gene ontology categories of DE genes [29].
Here DE genes between 4 aneuploid samples and UMC1/
UMC6 are calculated respectively, then those DE genes
expressed in UMC1 or UMC6 are selected to be DAVID
input datasets. Following the instructions of DAVID man-
ual, datasets of each sample were uploaded and the func-
tion charts were generated. The functional groups with a
P-value less than 0.05 and gene counts greater than 2 were
examined. Pathway maps of a manually curated proprietary
database (MetaCore™, GeneGo, St. Joseph, MI) were used
for pathway analysis of DE gene between different samples.
According to the P-value of each pathway, we chose the
first 50 pathways of each gene set.
Availability of supporting data




Additional File 1: Saturation curves of UMC1. Number of expressed
genes (blue curve) and correlation of expression (red curve) are plotted
with sequencing depth. Only mRNAs are selected for further analysis.
Additional File 2: Pearson’s correlation coefficient scatter plots
between two euploid iPSCs, UMC1 and UMC6.
Additional File 3: List of DE genes between each aneuploidy and
euploid iPSCs. DE genes by DEGseq between each aneuploidy and
euploid iPSCs are list in the table with p-value<0.05, q-value <0.05 and
fold change >=1.5.
Additional File 4: Clustered heatmap of GO enrichment analysis. GO
terms found in all four aneuploid cell lines are shown. The color
intensities indicate enrichment score of each GO term.
Additional File 5: KEGG/GO terms of DE genes on chromosome 3 in
trisomy 22 and on chromosome 10 in trisomy 8. KEGG/GO terms
found in DE genes chromosome 3 in trisomy 22 and on chromosome 10
in trisomy 8 with p-value<0.05 and counts >2.
Additional File 6: Pathway analysis using GeneGo Pathway tool.
Each number represents the amount of functional terms found in each
functional group.
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